MedTrace Logo

The VALIDATE-D Study

NCT01635062 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether vitamin D receptor agonist therapy lowers renin-angiotensin system activity.

Conditions

Interventions

DRUG

Calcitriol

Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.

DRUG

Placebo

Subjects will receive placebo for 3 weeks.

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Anand Vaidya, MD, MMSc · Brigham and Women's Hospital, Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635062 on ClinicalTrials.gov